Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis.
about
Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic DermatitisRegulatory myeloid cells in transplantationSite-specific immunosuppression in vascularized composite allotransplantation: prospects and potentialTacrolimus: a review of its use for the management of dermatoses.Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytesFunctional modulation of dendritic cells to suppress adaptive immune responses.Long-term safety of tacrolimus ointment in children treated for atopic dermatitis.The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies.Tacrolimus ointment: the treatment of atopic dermatitis and other inflammatory cutaneous disease.The role of topical calcineurin inhibitors in atopic dermatitis.The mode of topical immunomodulators in the immunological network of atopic dermatitis.Problem-based learning: a review of current issues relevant to physiotherapy education.Atopic dermatitis prevention.Atopic eczema: what's new?Assigning new roles to topical tacrolimus.Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.Innate immunity in atopic dermatitis.Role of dendritic cells in atopic dermatitis: an update.Cutaneous dendritic cells in allergic inflammation.Tacrolimus ointment in the management of atopic dermatitis.Treatment with topical tacrolimus favors chronic actinic dermatitis: a clinical and immunopathological study.Tacrolimus enhances irritation in a 5-day human irritancy in vivo model.Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study.TLR2 down-regulates FcεRI and its transcription factor PU.1 in human Langerhans cells.Characterization of monocyte subtypes in the allergic form of atopic eczema/dermatitis syndrome.[New immunosuppressive agents for treating psoriasis].Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis.[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids.Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study.Protective effects of different marigold (Calendula officinalis L.) and rosemary cream preparations against sodium-lauryl-sulfate-induced irritant contact dermatitis.Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis.Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.Atopic dermatitis: a review of topical nonsteroid therapy.
P2860
Q26739986-563EA625-D8C7-4279-AAC7-34084D086D13Q26999875-043445C3-FF04-47B7-997D-5F46AFD19D63Q27027795-982E3DB1-100B-4975-AFDE-A1B7637FFE1EQ34668921-608C9110-9F32-441D-A456-183400BA0A52Q34983782-E93FB819-EFFF-44AC-9094-F5988F957E5DQ35093120-1100846A-3E2F-4437-B1E2-9113BE6B262CQ35208400-34B814E6-FB88-4C19-98DA-3EF9545954AFQ35607569-344EB2E2-19F7-4D94-A7DA-3B0E1BA236BFQ35906926-46681A1E-4875-4BA4-B513-15A4508684F6Q35952647-7ADC0538-1EAB-485F-A3C4-362315D8C55AQ36051518-BBB8CC62-C881-4A69-8209-C1032F678689Q36356956-51D5361F-96CA-4AA3-8164-EF810C97C2AFQ36466794-52DF2DE7-ED99-4726-BED3-0B4C6298E781Q36473293-2EBCB213-5561-4BDB-B5CC-8560423C2D00Q36904866-BA8A413E-8FF1-4E8A-8D96-4E6DD8AC60A9Q37731539-BD8BDE2B-1281-424E-BDE6-A4C8F92881BFQ37823415-4C6A0589-E7AB-4DF3-BB3A-DD1E9C7A3ABBQ37823416-07EE0170-0930-47CB-9BC6-783E9BC1A5BAQ38026993-527E7B2D-420F-4F5A-B520-F5F73BE51639Q42081579-19FCA33C-4CC4-4AA6-BE9A-25758BDDC4B9Q43098463-B258E74C-7A8A-479C-8A3C-D3A837222F35Q44041440-A390F184-A1C7-4B70-B7B3-C6FCBD1C61DAQ44099119-CBA9C48A-B69A-4C0E-92EC-814F086473ABQ44140775-47616750-FAD4-4F9E-A291-8E5510E7F3CAQ44148207-72429FBE-5E71-44AD-A537-1DDDCE055CE1Q44360566-A358E68F-20D1-499E-9E0F-52551D471CC3Q44363575-0C710944-6665-48C1-B1E1-D93FBF21C2D8Q44420864-7AB7B37D-8DAE-4D08-9371-4E5AC06CF500Q44557361-0B18E228-0450-4497-837E-549AFB4F49F7Q45120688-CC6CD117-7819-4392-B193-F6721BD2EA6BQ46502987-25AA8C73-B7E2-4B21-9D99-5B79A4C68CC6Q46641474-A65E6B63-DA14-4416-8E0B-CB8D016A414DQ46982389-EF7D5A0B-7270-4AB0-B897-BC17D1866DEBQ52597622-B6E1D7FB-7FDD-4D3C-A070-88CE32DD9711
P2860
Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@ast
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@en
type
label
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@ast
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@en
prefLabel
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@ast
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@en
P2093
P356
P1476
Topical tacrolimus (FK506) lea ...... ic cells in atopic dermatitis.
@en
P2093
Haberstok J
Wollenberg A
von Bubnoff D
P304
P356
10.1067/MAI.2001.112942
P407
P577
2001-03-01T00:00:00Z